Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 5Fluorouracil 4pembrolizumab 3fludarabine 3Gemcitabine 3Docetaxel 3Cisplatin 3belinostat 2Quality of Life 2Psychiatric Rehabilitation 2Oxaliplatin 2Observation 2Leucovorin 2Irinotecan 2Filgrastim 2Erlotinib Hydrochloride 2Drug Therapy 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2umbralisib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1seribantumab 1rucaparib 1resiquimod 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × umbralisib × Sarcoma × Clear all
NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡